The cross-link below provides recent reported finds entitled "Trastuzumab [Herceptin] and Vinorelbine [Navelbine] as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes Analysis of Serum Tumor Markers as Predictive Factors and Cardiac Surveillance Algorithm."
These findings are reported in the August 1 2003 edition of the Journal of Clinical Oncology (Vol 21 Issue 15 pp. 2889-2895). The JCO is a publication of the American Society of Clinical Oncology (ASCO). |
All times are GMT -7. The time now is 05:23 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021